Local Access10 min readApril 9, 2026

    Buy Compounded Semaglutide in Dallas: Telehealth vs Local Clinics (2026)

    Dallas has a thriving weight loss clinic market, but local GLP-1 programs typically cost $300–600/month. TRIMI delivers the same compounded semaglutide anywhere in the DFW metroplex for $99/month — no clinic visit, no insurance hassle.

    Why Dallas Residents Choose Telehealth for GLP-1

    The Dallas-Fort Worth metroplex is a massive, car-dependent sprawl covering over 9,000 square miles. For residents in outer suburbs like Rockwall, Mansfield, or Lewisville, a visit to a weight loss clinic in Uptown Dallas can mean a 45-minute or longer drive each way. Telehealth solves the geography problem entirely — your provider is accessible from anywhere in the metroplex.

    Texas has the second-highest obesity rate among large states, and the Dallas metro reflects this trend. Dallas County has seen a substantial increase in type 2 diabetes diagnoses over the past decade, and cardiovascular disease remains the leading cause of death in North Texas. GLP-1 medications — now approved not just for weight loss but for cardiovascular risk reduction — are increasingly viewed as a front-line treatment for this cluster of conditions.

    Dallas GLP-1 Snapshot

    Population: ~1.3 million city / ~7.8 million DFW metro. Texas obesity rate: ~35%. Typical clinic rate: $300–600/mo. Brand Wegovy: $1,000–$1,400/mo. TRIMI telehealth: $99/mo semaglutide, $125/mo tirzepatide. Delivery: 3–5 business days anywhere in DFW.

    Dallas also has significant cost-of-living pressure in housing and transportation. For many families, the $300–600/month cost of in-clinic GLP-1 programs isn't sustainable long-term — and long-term use is exactly what the clinical evidence recommends for meaningful and maintained weight loss. TRIMI's $99/month telehealth model is designed to be financially sustainable for the duration of treatment.

    Local Clinic vs. Telehealth: Pricing Comparison

    OptionMonthly CostIn-Person VisitInsurance Required
    Dallas Weight Loss Clinic (avg)$300–$600YesSometimes
    Brand Wegovy (no insurance)$1,000–$1,400YesRecommended
    TRIMI Telehealth (compounded)$99/mo (sema) / $125/mo (tirz)NoNo

    Highland Park and Preston Hollow clinic programs at the premium end may run even higher when you factor in membership fees or concierge arrangements. Over 12 months, TRIMI's semaglutide at $99/month costs $1,188 versus $4,800+ at a mid-range Dallas clinic — a difference of more than $3,600 for the same active ingredient.

    How Telehealth Works: Consultation to Delivery in Dallas

    Step 1: Online Health Intake

    Fill out a detailed health questionnaire covering your medical history, current medications, and weight loss objectives. Completable from anywhere in DFW in about 10 minutes.

    Step 2: Texas Provider Review

    A licensed Texas provider reviews your submission, evaluates your candidacy for GLP-1 treatment, and prepares a starting dose protocol — usually within 24–48 hours.

    Step 3: Prescription to Pharmacy

    Prescription sent directly to a licensed compounding pharmacy. Flat rate: $99/mo for semaglutide or $125/mo for tirzepatide. No insurance, no prior auth required.

    Step 4: Delivered to Your DFW Door

    Medication arrives at your Dallas-area address in 3–5 business days. Ongoing care and dose adjustments managed through the TRIMI platform — no clinic visits required.

    Available Medications

    Compounded Semaglutide

    $99/month

    • Same active ingredient as Wegovy
    • Weekly self-injection
    • ~15% average weight loss at 68 weeks
    • No insurance required

    Compounded Tirzepatide

    $125/month

    • Dual GLP-1/GIP receptor agonist
    • Weekly self-injection
    • ~22% average weight loss at 72 weeks
    • No insurance required

    Read the full semaglutide vs. tirzepatide comparison to understand which medication may produce better results for your specific health profile.

    Getting Started with TRIMI in Dallas

    Dallas residents who meet the standard GLP-1 candidacy criteria can begin treatment through TRIMI in under 15 minutes. There's no referral needed, no in-person visit, and no insurance approval. Medication arrives at your DFW address within 3–5 business days of prescription approval.

    Before starting, review our guide on whether you qualify for GLP-1 treatment, and learn about how compounded semaglutide safety is ensured at licensed pharmacies.

    Ready to Start in Dallas?

    Get compounded semaglutide delivered to any DFW address for $99/month. Telehealth care, no clinic visit required.

    Get Started for $99/Month

    Medical Disclaimer

    This article is for informational purposes only and does not constitute medical advice. Semaglutide and tirzepatide are prescription medications requiring evaluation by a licensed healthcare provider. Individual results vary. Common side effects include nausea, vomiting, diarrhea, and constipation. Not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. Texas Department of State Health Services. Texas Behavioral Risk Factor Surveillance System: Obesity Data. 2023.
    5. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: April 9, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    Robyn Lynn CurtisFacebook
    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    Sarah MillerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Compare San Jose GLP-1 clinic pricing to Trimi's $99/mo telehealth semaglutide.

    Compare Columbus GLP-1 clinic pricing to Trimi's $99/mo telehealth semaglutide.

    Start your GLP-1 journey — from $99/mo

    Get Started